A director at Eli Lilly & Co bought 715 shares at 691.786USD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2025 Aggregated presentation by day and by market Statement of transactions in own shares from August 4th to August 8th 2025 Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1104/08/2025FR0010259150 2 000 104,50XPARIPSEN549300M6SGDPB4Z94P1105/08/2025FR0010259150 2 518 106,78046CCXEIPSEN549300M6SGDPB4Z94P1105/08/202...
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 32 - 2025 Présentation agrégée par jour et par marchéDéclaration des transactions sur actions propres réalisées du 04 août au 08 août 2025 Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marchéIPSEN549300M6SGDPB4Z94P1104/08/2025FR00102591502000104,5XPARIPSEN549300M6SGDPB4Z94P1105/08/2025FR00102591502518106,7804607CCXEIPSEN5...
With the orfo’ data being on the lower side of expectations, we upgrade to Hold as the narrative is likely to be dominated by the potential upside for Novo. However, we remain convinced that: 1) The obesity market is nowhere near as big as the market believes, 2) Ozempic no’s are far too high & 3) Margin forecasts need to fall. Cons’ Ozempic forecasts will take time to fall & we will likely need the IRA price in November to force consensus lower. Therefore, we see limited S-T downside to our DKK...
1H25 revenue missed forecasts, but its robust earnings of US$455.6m beat market estimates. It targets lower oncology revenue of US$270m-350m on delays in milestone income and setbacks in Sovleplenib’s review progress, and expects domestic sales to recover from 2H25. Seeing smooth R&D progress and market approvals in major oncology products, HUTCHMED will likely see a new wave of market approvals to fuel growth in the years ahead. Maintain BUY with a lower target price of HK$32.50.
Economics Trade July exports grew 7.2% yoy (+1.4ppts), with continued strength in exports to the ASEAN and EU markets. Import growth improved to 4.1% yoy (+3ppt), likely due to a lower base, and support from strong imports of integrated circuits and agricultural products. However, imports of some key commodities saw sharp declines. The Sino-US agreement on another 90-day trade truce may continue to support near-term trade activities. Sector Automobile China’s PV insurance registrations reboun...
Trinity Delta view: The China sales decline, plus lowering of revenue guidance are undoubtedly disappointing. However, China growth is already improving and management is confident this will continue during H225, driven by new indications. In particular, the recent Orpathys/Tagrisso approval based on SACHI data represent a much larger indication; importantly, data from the global SAFFRON trial are expected H126. Furthermore, as the sizeable ATTC opportunities become clearer, these could offer si...
HUTCHMED Reports 2025 Interim Results — Indications expansion driving growth and ATTC platform enriching pipeline — — $455 million in net income attributable to HUTCHMED driven by non-core partial disposal — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 2025 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. BST / 8:00 p...
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025 Aggregated presentation by day and by market Statement of transactions in own shares from July 28th to August 1st 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) IPSEN 549300M6SGDPB4Z94P11 28/07/2025 FR0010259150 3765 113,4151394 CCXE IPSEN 549300M6SGDPB4Z94P11 28/07/2025 FR0010259...
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 31 - 2025 Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 28 juillet au 01 août 2025 Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marchéIPSEN549300M6SGDPB4Z94P1128/07/2025FR00102591503765113,4151394CCXE IPSEN549300M6SGDPB4Z94P1128/07/2025FR00102591502000113,8973...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.